Case series identifies 10 persons with Omicron variant infection within 90 days of Delta infection
Small report finds 10 people got Omicron variant soon after Delta infection
A descriptive case series identified 10 persons across four states who were infected with the SARS-CoV-2 Omicron variant within 90 days of a…
Ten people in four states caught the Omicron variant within 90 days of a recent Delta infection, confirming this sequence can happen.
US COVID-19 death rate disparities decreased among most racial/ethnic groups from 2020 to 2021
Did COVID-19 death disparities shrink in the US from 2020 to 2021?
An observational report of the US population found that disparities in COVID-19 death rates decreased among most racial and ethnic groups fr…
COVID-19 death disparities among most racial and ethnic groups in the US decreased from 2020 to 2021, according to a new report.
Voluntary reporting of COVID-19 self-testing data described in US setting
What can we learn from people who report their at-home COVID test results?
A report describes a system for voluntary reporting of COVID-19 self-testing data in the United States. Key methodological details, includin…
A new voluntary system lets people share at-home COVID test results to help track the virus, though officials caution the early data might b…
Surveillance report describes COVID-19 hospitalizations in adults during Omicron BA.2 predominance
Surveillance report describes COVID-19 hospitalizations during Omicron BA.2 wave
An observational surveillance report from 14 states described COVID-19-associated hospitalizations among adults during a period of Omicron B…
A recent report tracks COVID-19 hospitalizations among adults during the Omicron BA.2 wave across 14 states, offering a snapshot of public h…
CDC review examines SARS-CoV-2 rebound in COVID-19 patients with and without antiviral treatment
CDC reviews studies on COVID-19 rebound after antiviral treatment
A CDC review examined studies of SARS-CoV-2 rebound in COVID-19 patients who did and did not receive antiviral treatment. The review did not…
The CDC reviewed studies on COVID-19 rebound after antiviral treatment, finding no new safety concerns but noting scientists are still learn…
In-hospital mortality risk assessed for US patients hospitalized primarily for COVID-19
What happens to people hospitalized for COVID-19 in the US?
An observational report examined in-hospital mortality risk among patients hospitalized primarily for COVID-19 in the United States. The rep…
A new report examines the risk of dying in the hospital for patients whose main reason for admission was COVID-19, but it has not yet shared…
Reported Racial Discrimination in Healthcare Linked to Higher COVID-19 Unvaccinated Prevalence
Adults reporting health care discrimination more likely to be unvaccinated against COVID-19
An observational study of U.S. adults found that reported experiences of racial and ethnic discrimination in healthcare were associated with…
Adults who reported facing racial or ethnic discrimination in health care were more likely to be unvaccinated against COVID-19.
Observational report examines COVID-19 antiviral treatment patterns in US older adults
Study examines COVID-19 antiviral treatment rates in older adults across age groups
An observational report from a US national research network examined COVID-19 antiviral treatment patterns among adults aged 65 years and ol…
A new report tracks how often older adults with COVID-19 receive recommended antiviral treatments, but full results are not yet shared.
Favipiravir PEP shows non-significant reduction in SARS-CoV-2 infection among household contacts in Thailand trial
Can a pill protect you after a family member gets COVID?
A phase 2/3 cluster-randomized trial in 168 Thai household contacts of COVID-19 cases compared favipiravir PEP (1600-2000 mg/day for 7 days)…
Taking an antiviral pill after a family member gets COVID might lower infection rates and delay symptoms, though the study's main findings w…
Retrospective study finds 61% of vaccinated, boostered individuals neutralize Wuhan-Hu-1 SARS-CoV-2 variant
How well do vaccine antibodies fight different COVID variants?
A retrospective cohort study of 100 vaccinated and boostered individuals found 61% effectively neutralized the Wuhan-Hu-1 SARS-CoV-2 variant…
Most vaccinated people's antibodies stopped the original virus, but only a few could also block newer variants like Beta, Delta, and Omicron…
Phase 1 study finds molnupiravir 800 mg well-tolerated with no NHC accumulation in healthy Chinese adults
How does a COVID-19 pill behave in the body? A small study in healthy men offers clues.
An open-label, fixed-sequence Phase 1 study in 16 healthy male Chinese adults evaluated the pharmacokinetics and safety of oral molnupiravir…
Understanding how a drug moves through the body is a crucial first step. A small, early study in healthy Chinese men found the active part o…
Bivalent COVID-19 mRNA booster shows similar early safety to monovalent in children aged 5-11
Is the updated COVID-19 booster safe for young kids? Early monitoring suggests yes.
A US safety monitoring report in children aged 5-11 found similar early safety findings for bivalent COVID-19 mRNA vaccine booster doses com…
Early safety monitoring shows the updated COVID-19 booster for kids aged 5 to 11 has a safety profile similar to the original vaccine.